Clinical Trial

A Study of IDP-001 in Advanced or Metastatic Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This clinical study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of IDP-001 in participants with advanced or metastatic squamous and non-squamous NSCLC and other squamous cell solid tumors (for example, head and neck, esophageal, cervical, cutaneous).
Protocol Amendment History 2 changes
critical Recruitment opened 2026-07-30
notable Trial sites expanded: 1 -> 4 locations 2026-07-28
Trial Details
NCT Number NCT07602842
Lead Sponsor InduPro, Inc.
Conditions Advanced Solid Tumor, Metastatic Solid Tumor, Head and Neck Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Cervix, Non Squamous Non Small Cell Lung Cancer, Squamous Cell Carcinoma of the Esophagus, Squamous Cell Carcinoma of the Anus +1 more
Enrollment 132 participants
Start Date 2026-06
Primary Completion 2028-06 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-29